Literature DB >> 21647142

ERasing breast cancer resistance through the kinome.

Amber B Johnson, Bert W O'Malley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21647142     DOI： 10.1038/nm0611-660

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

Review 1.  Trastuzumab--mechanism of action and use in clinical practice.

Authors:  Clifford A Hudis
Journal:  N Engl J Med       Date:  2007-07-05       Impact factor: 91.245

Review 2.  Molecularly targeted endocrine therapies for breast cancer.

Authors:  L Orlando; P Schiavone; P Fedele; N Calvani; A Nacci; P Rizzo; A Marino; M D'Amico; F Sponziello; E Mazzoni; M Cinefra; N Fazio; E Maiello; N Silvestris; G Colucci; S Cinieri
Journal:  Cancer Treat Rev       Date:  2010-11       Impact factor: 12.111

3.  Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.

Authors:  N Sarwar; J-S Kim; J Jiang; D Peston; H D Sinnett; P Madden; J M Gee; R I Nicholson; A E Lykkesfeldt; S Shousha; R C Coombes; S Ali
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

4.  Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.

Authors:  Véronique Marsaud; Angélique Gougelet; Sébastien Maillard; Jack-Michel Renoir
Journal:  Mol Endocrinol       Date:  2003-07-10

Review 5.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.

Authors:  Jianming Xu; Ray-Chang Wu; Bert W O'Malley
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 6.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

Authors:  V Craig Jordan; Bert W O'Malley
Journal:  J Clin Oncol       Date:  2007-09-24       Impact factor: 44.544

7.  PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.

Authors:  Karine Belguise; Gail E Sonenshein
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Shangqin Guo; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

9.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

10.  Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.

Authors:  Georgios Giamas; Aleksandra Filipović; Jimmy Jacob; Walter Messier; Hua Zhang; Dongyun Yang; Wu Zhang; Belul Assefa Shifa; Andrew Photiou; Cathy Tralau-Stewart; Leandro Castellano; Andrew R Green; R Charles Coombes; Ian O Ellis; Simak Ali; Heinz-Josef Lenz; Justin Stebbing
Journal:  Nat Med       Date:  2011-05-22       Impact factor: 53.440
View more
  8 in total

1.  Regulation of transcriptional activation function of rat estrogen receptor α (ERα) by novel C-terminal splice inserts.

Authors:  Pallob Kundu; Min Li; Rong Lu; Enrico Stefani; Ligia Toro
Journal:  Mol Cell Endocrinol       Date:  2014-11-07       Impact factor: 4.102

2.  Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.

Authors:  Kexin Zhang; Lujun Chen; Haifeng Deng; Yongyi Zou; Juan Liu; Hongbing Shi; Bin Xu; Mingyang Lu; Chong Li; Jingting Jiang; Zhigang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Identification of curcumin derivatives as human LMTK3 inhibitors for breast cancer: a docking, dynamics, and MM/PBSA approach.

Authors:  K Anbarasu; S Jayanthi
Journal:  3 Biotech       Date:  2018-04-27       Impact factor: 2.406

4.  Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patients.

Authors:  Balazs Jóri; Rick Kamps; Sofia Xanthoulea; Bert Delvoux; Marinus J Blok; Koen K Van de Vijver; Bart de Koning; Felicia Trups Oei; Carli M Tops; Ernst Jm Speel; Roy F Kruitwagen; Encarna B Gomez-Garcia; Andrea Romano
Journal:  Oncotarget       Date:  2015-12-01

5.  OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation.

Authors:  Jianing Tang; Zeyu Wu; Zelin Tian; Wei Chen; Gaosong Wu
Journal:  Cell Death Dis       Date:  2021-05-25       Impact factor: 8.469

6.  Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.

Authors:  Sameer Mirza; Emad A Rakha; Alaa Alshareeda; Shakur Mohibi; Xiangshan Zhao; Bryan J Katafiasz; Jun Wang; Channabasavaiah Basavaraju Gurumurthy; Aditya Bele; Ian O Ellis; Andrew R Green; Hamid Band; Vimla Band
Journal:  Breast Cancer Res Treat       Date:  2013-01-04       Impact factor: 4.872

Review 7.  Polyubiquitination inhibition of estrogen receptor alpha and its implications in breast cancer.

Authors:  Angeles C Tecalco-Cruz; Josué O Ramírez-Jarquín
Journal:  World J Clin Oncol       Date:  2018-08-13

Review 8.  The multifaceted role of lemur tyrosine kinase 3 in health and disease.

Authors:  Angeliki Ditsiou; Teresa Gagliano; Mark Samuels; Viviana Vella; Christos Tolias; Georgios Giamas
Journal:  Open Biol       Date:  2021-09-29       Impact factor: 6.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.